Department of Ultrasound Medicine, The First Affiliated Hospital of University of Science and Technology of China Anhui Provincial Hospital, Hefei, China.
Front Endocrinol (Lausanne). 2022 Jun 3;13:880911. doi: 10.3389/fendo.2022.880911. eCollection 2022.
Annual T1 stage papillary thyroid carcinoma (PTC) incidence rates continue to rise, yet the optimal treatment for this cancer type remains controversial. Central lymph node metastasis (CLNM) is a critical determinant in the context of treatment decision-making. While several prior studies have evaluated patients with clinica l T1a(cT1a) stage PTC, there have been fewer analyses of clinical T1b(cT1b) disease to date. The present study was thus formulated to explore predictors of CLNM in patients with cT1a and cT1b stage PTC.
A retrospective analysis of data including clinicopathological characteristics and BRAF mutation status was conducted for 452 PTC patients undergoing surgical treatment. Logistic univariate and multivariate analyses were performed to identify risk factors associated with CLNM in particular patients' characteristics and the accuracy of the established logistic regression models was evaluated using the R software platform.
Respective CLNM incidence rates in cT1a and cT1b disease were 39.39% and 67.21%. Factors associated with a higher risk of CLNM among PTC(cT1a) patients included male sex, young age, tumor size, contact with capsule, and multifocality as determined through comparisons of the area under the curve for logistic regression models. Whereas male sex and age were associated with CLNM risk in PTC(cT1b) patients in univariate and multivariate analyses, age was the only risk factor associated with CLNM incidence among women with PTC(cT1b).
Predictors of CLNM differ between PTC patients with cT1a and cT1b stage disease, and a comprehensive assessment of these risk factors should thus be conducted when designing individualized treatment regimens for PTC patients.
甲状腺乳头状癌(PTC)的 T1 期年度发病率持续上升,但这种癌症类型的最佳治疗方法仍存在争议。中央淋巴结转移(CLNM)是治疗决策中的一个关键决定因素。虽然之前有几项研究评估了临床 T1a(cT1a)期 PTC 患者,但迄今为止对临床 T1b(cT1b)疾病的分析较少。因此,本研究旨在探讨 cT1a 和 cT1b 期 PTC 患者 CLNM 的预测因素。
对 452 例接受手术治疗的 PTC 患者的临床病理特征和 BRAF 突变状态进行回顾性分析。采用 Logistic 单因素和多因素分析,确定与 CLNM 相关的风险因素,特别是在特定患者特征中,并使用 R 软件平台评估建立的 Logistic 回归模型的准确性。
cT1a 和 cT1b 疾病的相应 CLNM 发生率分别为 39.39%和 67.21%。在 PTC(cT1a)患者中,与 CLNM 风险较高相关的因素包括男性、年龄较小、肿瘤大小、与包膜接触和多灶性,这是通过比较 Logistic 回归模型的曲线下面积得出的。而在单因素和多因素分析中,男性和年龄与 PTC(cT1b)患者的 CLNM 风险相关,但年龄是 PTC(cT1b)女性患者 CLNM 发生率的唯一相关风险因素。
cT1a 和 cT1b 期 PTC 患者的 CLNM 预测因素不同,因此在为 PTC 患者制定个体化治疗方案时,应综合评估这些风险因素。